Compare Inovio Pharmaceuticals Inc (INO) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs UiPath Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while UiPath Inc trades at $11.97 (market cap $6.30B). The key difference: UiPath Inc is far larger — about 70.6× Inovio Pharmaceuticals Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PATH | |
|---|---|---|
Market Cap | $89.27M | $6.30B |
Sector | Health | Technology |
52-Week High | $2.87 | $19.29 |
52-Week Low | $1.05 | $9.38 |
Enterprise Value | $60.28M | $5.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
UiPath (PATH) trades at $12.26, up 0.91% today, with a bullish technical outlook and strong support at $12. The company shows improving fundamentals, with revenue growing to $1.43B in 2025 and a projected net profit of $327M in 2026. Recent news highlights AI partnerships and agentic automation growth, though Q1 2026 EPS missed expectations.
Outlook is cautiously optimistic with a consensus price target of $13.33, offering ~9% upside. Key opportunities include high gross margins and AI adoption, while risks involve execution on profitability and competitive pressures. Institutional sentiment is mixed with 25% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
